Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 685509 in clinically significant portal hypertension with compensated alcohol-related cirrhosis
MOH_2022-05-17_010807Phase 2Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of avenciguat in Portal Hypertension (PH) and Cirrhosis (3 arms), sponsored by Boehringer Ingelheim. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
avenciguat
03
Conditions
Portal Hypertension (PH)Cirrhosis
Beyond the preview
Go deeper on MOH_2022-05-17_010807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-05-17_010807.